Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.975 +0.005 (+0.10%)
Streaming Delayed Price Updated: 1:25 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
22 23 Next >
7 Very Oversold Nasdaq Stocks to Buy Right Now
The worries that have pushed the Nasdaq down sharply are overdone. Here are seven oversold Nasdaq oversold Nasdaq investment opportunities. 
Via InvestorPlace
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease
From bluebird bio, Inc.
Via Business Wire
Fox, Warner Music, Eli Lilly, Chegg And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 400 points on Tuesday. Here are some big stocks recording gains in today’s session. Paymentus Holdings, Inc. (NYSE: PAY) shares rose 29.4% to... 
Via Benzinga
1 Beaten-Down Stock That Could Soar by 89%, According to Wall Street
Are you feeling brave? 
Via The Motley Fool
Why Bluebird Bio Stock Is Taking Flight Today
An analyst upgrade is fueling a double-digit rise in the biotech's shares today. 
Via The Motley Fool
bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
2 Magnificent Growth Stocks I'm Buying Hand Over Fist Right Now
These two growth stocks could deliver stellar returns over the long term. 
Via The Motley Fool
3 Stocks to Buy for Lottery Jackpot Style Returns
Although you can try your hand at the lottery, your odds of success are probably far better with stocks with high returns. 
Via InvestorPlace
bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update
From bluebird bio, Inc.
Via Business Wire
3 Small-Cap Stocks That Could Be Big-Time Winners
These stocks come with significant risks. But they could generate huge returns over time. 
Via The Motley Fool
bluebird bio Inc. (NASDAQ: BLUE) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
The Latest Analyst Ratings for bluebird bio
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Amarin Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) rose 43% to $6.91. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2023
Via Benzinga
AT&T, Carvana, Northern Trust, And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining over 250 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why bluebird bio Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Gainers 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) shares surged 23.6% to $2.99 in pre-market trading after dipping 21% on Tuesday. 
Via Benzinga
Cisco To Rally Around 21%? Here Are 10 Other Analyst Forecasts For Wednesday
Wedbush boosted the price target for Domino's Pizza, Inc. (NYSE: DPZ) from $365 to $430. Wedbush analyst Nick Setyan maintained an Outperform rating. Domino's shares rose 0.7% to close at $392.29 on... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we check out all of the latest news for Wednesday! 
Via InvestorPlace
Down 51% in 2023, Here's Why Bluebird Bio Stock Could Soon Double, Says Wall Street
This company could soon commercialize its third gene therapy. 
Via The Motley Fool
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
Reaching profitability could be harder than investors expect. 
Via The Motley Fool
Is Bluebird Bio Stock a Buy Now?
If the company can pull off a comeback, investors who get in now will see incredible returns. But how likely is a comeback? 
Via The Motley Fool
bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
2 Short-Squeeze Candidates That Could Go Parabolic
Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately. 
Via The Motley Fool
Breakthrough in CRISPR-Based Therapy: FDA Accepts Vertex and CRISPR Therapeutics' Exa-cel Application
The FDA has accepted the application for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG (NASDAQ: CRSP) exa-cel for sickle cell disease and transfusion-dependent  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2023
Via Benzinga
Caterpillar To Rally Over 37%? Here Are 10 Other Analyst Forecasts For Thursday
Keybanc boosted the price target for Pure Storage, Inc. (NYSE: PSTG) from $35 to $40. Keybanc analyst Thomas Blakey maintained the stock with an Overweight rating. Pure Storage shares fell 2.1% to... 
Via Benzinga
Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial
A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that... 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.